Erratum: A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

Daniel Umbricht,Marta del Valle Rubido,Eric Hollander,James T McCracken,Frederick Shic,Lawrence Scahill,Jana Noeldeke,Lauren Boak,Omar Khwaja,Lisa Squassante,Christophe Grundschober,Heidemarie Kletzl,Paulo Fontoura

Neuropsychopharmacology（2017）

引用 56|浏览0

暂无评分

摘要

Correction to: Neuropsychopharmacology advance online publication, 16 November 2016; doi:10.1038/npp.2016.232 In this paper, page 4: Table 1, Vineland II Adaptive Behavior score is a title; therefore the score ‘62 (12.9)’ should be removed. In the second paragraph of the RESULTS section, the VABS-IIscore should be ‘63 (12.

查看译文

关键词

Adverse effects,Autism spectrum disorders,Clinical pharmacology,Pharmacokinetics,Medicine/Public Health,general,Psychiatry,Neurosciences,Behavioral Sciences,Pharmacotherapy,Biological Psychology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要